180 Life Sciences Corp SEC Filings

Amendment No. 2 to Schedule 13D discloses that Anthony Brian Goodman and Elray Resources, Inc. hold a shared beneficial position in ETHZilla Corporation common stock after a cashless exercise of warrants. Elray exercised warrants on July 27, 2025, resulting in issuance of 1,320,000 shares on July 28, 2025. Elray sold portions of those shares on August 7, 8 and 11, 2025, totaling 1,317,?—the filing lists sales of 135,257, 777,595 and 405,148 shares at weighted average prices of $3.56, $3.18 and $3.17 respectively. The parties earlier entered a Settlement and Mutual Release Agreement where the company agreed to repurchase 1,318,000 shares for $1.0 million in staged payments; those shares are subject to a Voting Agreement and an irrevocable proxy in favor of the CEO through April 28, 2026.

180 Life Sciences Corp. amended an 8-K to disclose documentation and agreements tied to a Private Placement and related transactions, including a digital asset treasury strategy and forms of warrants, purchase and registration rights agreements, strategic advisor agreements, offer letters for two executives, and an Asset Management Agreement with Electric Treasury Edge, LLC. The filing warns these matters include forward-looking statements and lists material risks, notably the high volatility of Ether and other cryptocurrencies, potential correlation between the company’s stock and held digital assets, regulatory and tax uncertainty, and the risk the Private Placement may not produce anticipated benefits.

Form 144 notice for 180 Life Sciences Corp. (symbol: ATNFW) discloses a proposed sale of 189,959 common shares, with an aggregate market value of $1,358,187.85. The shares were acquired as a restricted stock grant from the issuer on 02/20/2025 and the filer indicates an approximate sale date of 08/14/2025 through Oppenheimer & Co., Inc. The filing reports 6,039,208 shares outstanding and states there were no sales in the past three months by the filer. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

180 Life Sciences Corp. announced a corporate rebranding to ETHZilla Corporation and multiple warrant exercises that resulted in shares being issued or in the process of being issued. Several holders exercised warrants for cash at exercise prices ranging from $1.50 to $2.65, including large exercises of 1,335,862 warrants at $1.50 and 864,250 warrants at $2.28. The company states the issuances were exempt from registration under Section 4(a)(2) and that the resale of the resulting shares has been registered under the Securities Act. The company will change its Nasdaq tickers to ETHZ (common stock) and ETHZW (public warrants) at market open on August 18, 2025, and launched a new corporate website, www.ETHZilla.com, where investor materials and governance documents will be posted.

Rudisill McAndrew, Executive Chairman, reports indirect holdings in 180 Life Sciences Corp. (ticker: ATNF) through multiple managed entities. He is disclosed as the managing partner of BER I LLC, GER I LLC, MRR I LLC and Pelagic Capital Advisors LLC, each shown as indirect owners of common stock totaling 565, (?) wait—this includes numbers below.

Crystal Heter filed an initial Form 3 reporting a relationship as a director of 180 Life Sciences Corp. (identified in the filing as ATNF). The event requiring the statement is dated 08/04/2025 and the form is signed 08/12/2025. The filing includes the reporting person's Palo Alto, CA address and explicitly states that no securities are beneficially owned by the reporting person as of the filing. The form is an initial Section 16 filing and contains no entries in the tables for non-derivative or derivative securities.

Steadfast Capital Management LP and affiliated entities reported beneficial ownership of 11,320,754 shares of 180 Life Sciences Corp. common stock, equal to 7.3% of 154,032,084 shares outstanding. The filing names the Investment Manager, American Steadfast, Steadfast International Master Fund and Robert S. Pitts Jr.; Mr. Pitts is the controlling principal of the Investment Manager. The Investment Manager has shared voting and dispositive power over the shares held by the two funds. The statement certifies the holdings are not held to change or influence control of the issuer.

180 Life Sciences Corp. initiated a cryptocurrency treasury strategy and has accumulated a sizeable ETH position. As of August 11, 2025, the company acquired 82,186 ETH at an average acquisition price of $3,806.71, which the filing values at approximately $349 million. In addition to the ETH, the company holds about $238 million in USD cash equivalents. The filing states these ETH purchases were made using certain net proceeds from a previously disclosed private PIPE offering and the sale of convertible notes. The disclosure was furnished on Form 8-K and includes a press release as Exhibit 99.1.